U.S. Markets closed

Cipla Limited (CIPLA.NS)

NSE - NSE Real Time Price. Currency in INR
Add to watchlist
590.45+20.40 (+3.58%)
At close: 3:30PM IST
Full screen
Previous Close570.05
Open569.50
Bid0.00 x 0
Ask0.00 x 0
Day's Range561.05 - 593.70
52 Week Range480.20 - 621.25
Volume1,838,012
Avg. Volume1,255,456
Market Cap475.12B
BetaN/A
PE Ratio (TTM)47.24
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters3 days ago

    Morning News Call - India, August 14

    To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_08142017.pdf If you would like to receive this newsletter via email, please register ...

  • Reuters6 months ago

    India's Cipla looks to boost US business as Q3 profit beats estimates

    Indian drugmaker Cipla Ltd's third-quarter profit beat estimates due to higher sales in the United States, and the company said it was looking for licensing deals and acquisitions to build its speciality medicines pipeline in that market. The country's fifth-largest drugmaker by sales reported a roughly 21 percent rise in revenue from North America for the October-December period. Cipla bought two U.S. generic drug producers, Invagen and Exelan, for about $550 million last year in its first big move to expand in a market where most of its local peers already have a large presence.

  • Reuterslast year

    Indian court extends relief to pharma firms in drug ban case

    Several companies, including Indian units of Abbott Laboratories and Pfizer Inc , and domestic firms like Cipla Ltd and Macleods Pharmaceuticals, went to the Delhi High Court to try to get the ban lifted. On Monday, judge Rajiv Sahai Endlaw moved the hearing into his chamber from a courtroom packed with lawyers and company executives. Archana Sachdeva, a lawyer representing Cipla among other firms, said he had ordered the next hearing on March 28.